The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Genetics and Outcome of Atypical Hemolytic Uremic Syndrome: A Nationwide French Series Comparing Children and Adults
Open accessAbstract
Summary: Background and objectives: Atypical hemolytic uremic syndrome (aHUS) is a rare complement-mediated kidney disease that was first recognized in children but also affects adults. This study assessed the disease presentation and outcome in a nationwide cohort of patients with aHUS according to the age at onset and the underlying complement abnormalities. Design, setting, participants, & measurements: A total of 214 patients with aHUS were enrolled between 2000 and 2008 and screened for mutations in the six susceptibility factors for aHUS and for anti–factor H antibodies. Results: Onset of aHUS occurred as frequently during adulthood (58.4%) as during childhood (41.6%). The percentages of patients who developed the disease were 23%, 40%, 70%, and 98% by age 2, 18, 40, and 60 years, respectively. Mortality was higher in children than in adults (6.7% versus 0.8% at 1 year) (P=0.02), but progression to ESRD after the first aHUS episode was more frequent in adults (46% versus 16%; P<0.001). Sixty-one percent of patients had mutations in their complement genes. The renal outcome was not significantly different in adults regardless of genetic background. Only membrane cofactor protein (MCP) and undetermined aHUS were less severe in children than adults. The frequency of relapse after 1 year was 92% in children with MCP-associated HUS and approximately 30% in all other subgroups. Conclusion: Mortality rate was higher in children than adults with aHUS, but renal prognosis was worse in adults than children. In children, the prognosis strongly depends on the genetic background.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atypical Hemolytic–Uremic Syndrome
Noris, M., & Remuzzi, G. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0902814 · Cited by 1,338
Noris, M., Caprioli, J., Bresin, E., Mossali, C., Pianetti, G., Gamba, S., Daina, E., Fenili, C., Castelletti, F., Sorosina, A., et al. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02210310 · Cited by 1,042
Caprioli, J., Noris, M., Brioschi, S., Pianetti, G., Castelletti, F., Bettinaglio, P., Mele, C., Bresin, E., Cassis, L., Gamba, S., et al. (2006) · Blood · doi:10.1182/blood-2005-10-007252 · Cited by 732
Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies
on behalf of the French Study Group for aHUS/C3G, Zuber, J., Fakhouri, F., Roumenina, L. T., Loirat, C., & Frémeaux-Bacchi, V. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.214 · Cited by 496
Self-citationMutations in Complement Factor I Predispose to Development of Atypical Hemolytic Uremic Syndrome
Kavanagh, D., Kemp, E. J., Mayland, E., Winney, R. J., Duffield, J. S., Warwick, G., Richards, A., Ward, R., Goodship, J. A., & Goodship, T. H. J. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005010103 · Cited by 475
Pregnancy-Associated Hemolytic Uremic Syndrome Revisited in the Era of Complement Gene Mutations
Fakhouri, F., Roumenina, L., Provot, F., Sallée, M., Caillard, S., Couzi, L., Essig, M., Ribes, D., Dragon-Durey, M.-A., Bridoux, F., et al. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009070706 · Cited by 467
Self-citationMutations in complement C3 predispose to development of atypical hemolytic uremic syndrome
Frémeaux-Bacchi, V., Miller, E. C., Liszewski, M. K., Strain, L., Blouin, J., Brown, A. L., Moghal, N., Kaplan, B. S., Weiss, R. A., Lhotta, K., et al. (2008) · Blood · doi:10.1182/blood-2008-01-133702 · Cited by 372
Self-citationMaga, T. K., Nishimura, C. J., Weaver, A. E., Frees, K. L., & Smith, R. J. H. (2010) · Human Mutation · doi:10.1002/humu.21256 · Cited by 308
Pickering, M. C., de Jorge, E. G., Martinez-Barricarte, R., Recalde, S., Garcia-Layana, A., Rose, K. L., Moss, J., Walport, M. J., Cook, H. T., de Córdoba, S. R., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070301 · Cited by 278
Abarrategui-Garrido, C., Martínez-Barricarte, R., López-Trascasa, M., Rodríguez de Córdoba, S., & Sánchez-Corral, P. (2009) · Blood · doi:10.1182/blood-2009-05-223834 · Cited by 206
Fremeaux-Bacchi, V, Kemp, E. J., Goodship, J. A., Dragon-Durey, M.-A., Strain, L., Loirat, C., Deng, H.-W., & Goodship, T. H. J. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2005.030783 · Cited by 171
Self-citationRoumenina, L. T., Jablonski, M., Hue, C., et al. (2009) · Blood · doi:10.1182/blood-2009-01-197640 · Cited by 157
Alternative complement pathway assessment in patients with atypical HUS
Roumenina, L. T., Loirat, C., Dragon‐Durey, M., Halbwachs‐Mecarelli, L., Sautès‐Fridman, C., & Frémeaux‐Bacchi, V. (2011) · Journal of Immunological Methods · doi:10.1016/j.jim.2010.12.020 · Cited by 157
Self-citationMutations in complement C3 predispose to development of atypical haemolytic uraemic syndrome
Frémeaux‐Bacchi, V., Goodship, T. H. J., Régnier, C. H., Dragon‐Durey, M., Janssen, B. J. C., & Atkinson, J. P. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2007.06.038 · Cited by 153
Self-citationA prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function
Roumenina, L. T., Frimat, M., Miller, E. C., Provôt, F., Dragon‐Durey, M., Bordereau, P., Bigot, S., Hue, C., Satchell, S. C., Mathieson, P. W., et al. (2012) · Blood · doi:10.1182/blood-2011-10-383281 · Cited by 142
Self-citationEsparza-Gordillo, J., de Jorge, E. G., Abarrategui-Garrido, C., CARRERAS, L., López‐Trascasa, M., Sánchez‐Corral, P., & de Córdoba, S. R. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2005.11.008 · Cited by 131
Ermini, L., Goodship, T. H. J., Strain, L., Weale, M. E., Sacks, S. H., Cordell, H. J., Frémeaux‐Bacchi, V., & Sheerin, N. (2011) · Molecular Immunology · doi:10.1016/j.molimm.2011.11.003 · Cited by 41
Cited by
Magro, C., Mulvey, J. J., Berlin, D., Nuovo, G., Salvatore, S., Harp, J., Baxter-Stoltzfus, A., & Laurence, J. (2020) · Translational Research · doi:10.1016/j.trsl.2020.04.007 · Cited by 2,183
Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome
Legendre, C. M., Licht, C., Muus, P., Greenbaum, L. A., Babu, S., Bedrosian, C., Bingham, C., Cohen, D. J., Delmas, Y., Douglas, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208981 · Cited by 1,586
Self-citationAtypical Hemolytic–Uremic Syndrome
Noris, M., & Remuzzi, G. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0902814 · Cited by 1,338
Complement System Part II: Role in Immunity
Merle, N. S., Noe, R., Halbwachs-Mecarelli, L., Fremeaux-Bacchi, V., & Roumenina, L. T. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00257 · Cited by 1,051
Self-citationGoodship, T. H. J., Cook, H. T., Fakhouri, F., Fervenza, F. C., Frémeaux-Bacchi, V., Kavanagh, D., Nester, C. M., Noris, M., Pickering, M. C., Rodríguez de Córdoba, S., et al. (2017) · Kidney International · doi:10.1016/j.kint.2016.10.005 · Cited by 701
Self-citation
Metadata
- Authors
- Fremeaux-Bacchi, V., Fakhouri, F., Garnier, A., Bienaimé, F., Dragon-Durey, M.-A., Ngo, S., Moulin, B., Servais, A., Provot, F., Rostaing, L., Burtey, S., Niaudet, P., Deschênes, G., Lebranchu, Y., Zuber, J., & Loirat, C.
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2013-04
- Volume
- 8
- Issue
- 4
- Pages
- 554-562
- ISSN
- 1555-9041 (ISSN-L)
- OpenAlex
- W2106675927
- Cited by
- 714
- References
- 17
- FWCI
- 28.79
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.